Dewpoint Therapeutics (US)

https://www.dewpointx.com

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A. Founding investor Polaris Partners led the equity round and was joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer. Dewpoint is harnessing recent insights into biomolecular condensates elucidated by founders Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden and Richard Young of the Whitehead Institute with the goal to uncover treatments for the toughest diseases. Biomolecular condensates have long been known but historically understudied because they are difficult to analyze with traditional drug discovery methods like protein crystallography and biochemical activity assays. Condensates are well-defined, membrane-less organelles found inside cells that take advantage of intrinsically disordered regions of proteins to organize certain proteins and nucleic acids in cells, bringing them together in high concentrations to significantly enhance the chemical reactions critical for the cells’ lives. Emerging understanding of condensates offers new insights into cellular function and disease that have not been considered by scientists and drug developers. *

	Start	2019-01-30 existent
	Group	Dewpoint Therapeutics (Group)
	Predecessor	Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG, Dresden)
	Industry	BIOTECH
	Person	Hyman, Anthony (Tony) (Max Planck 201901 Group Leader at MPI-CBG Dresden + Co-Founder Dewpoint Therapeutics)

	Region	Boston, MA
	Country	United States (USA)
	Street	6 Tide Street Suite 300
	City	02210 Boston, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Dewpoint Therapeutics. (1/30/19). "Press Release: Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates". Cambridge, MA.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Dewpoint Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)